Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Net Income towards Common Stockholders: 2016-2024

Historic Net Income towards Common Stockholders for Rhythm Pharmaceuticals (RYTM) over the last 8 years, with Dec 2024 value amounting to -$264.6 million.

  • Rhythm Pharmaceuticals' Net Income towards Common Stockholders fell 20.70% to -$54.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$197.7 million, marking a year-over-year increase of 24.40%. This contributed to the annual value of -$264.6 million for FY2024, which is 43.26% down from last year.
  • According to the latest figures from FY2024, Rhythm Pharmaceuticals' Net Income towards Common Stockholders is -$264.6 million, which was down 43.26% from -$184.7 million recorded in FY2023.
  • Over the past 5 years, Rhythm Pharmaceuticals' Net Income towards Common Stockholders peaked at -$69.6 million during FY2021, and registered a low of -$264.6 million during FY2024.
  • In the last 3 years, Rhythm Pharmaceuticals' Net Income towards Common Stockholders had a median value of -$184.7 million in 2023 and averaged -$210.1 million.
  • Data for Rhythm Pharmaceuticals' Net Income towards Common Stockholders shows a maximum YoY crashed of 160.18% (in 2022) over the last 5 years.
  • Rhythm Pharmaceuticals' Net Income towards Common Stockholders (Yearly) stood at -$69.6 million in 2021, then crashed by 160.18% to -$181.1 million in 2022, then declined by 1.97% to -$184.7 million in 2023, then tumbled by 43.26% to -$264.6 million in 2024.